Spectrum Wealth Counsel’s SAB Biotherapeutics SABS Stock Holding History

Spectrum Wealth Counsel’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-503	Closed	-$2.28K	–	407
2024 Q1	$2.28K	Hold	503	–	–	﹤0.01%	342
2023 Q4	$3.46K	Buy	+503	New	+$4.22K	﹤0.01%	300

Other funds holding SABS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Spectrum Wealth Counsel's SABS Position: Q2 2024 in Review

Spectrum Wealth Counsel sold out of SAB Biotherapeutics (SABS) in Q2 2024, closing a stake of 503 shares — an estimated $2.28K sold.

Spectrum Wealth Counsel first reported a position in SABS in Q4 2023 and held it in 2 quarters. The position peaked at $3.46K in Q4 2023. 22 funds tracked by Wall St. Rank hold SABS as of Q2 2024.

Spectrum Wealth Counsel reported no remaining SAB Biotherapeutics position as of Q2 2024 after selling out during the quarter.
Spectrum Wealth Counsel sold 503 SAB Biotherapeutics shares in Q2 2024, an estimated $2.28K.
Spectrum Wealth Counsel first reported a position in SAB Biotherapeutics in Q4 2023 and held it in 2 quarters.
Spectrum Wealth Counsel's SAB Biotherapeutics position peaked at $3.46K in Q4 2023.
22 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2024.

Based on Spectrum Wealth Counsel's 13F filing for Q2 2024, filed 8 Aug 2024.